

Clerk of the House of Representatives
Legislative Resource Center
B-106 Gannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED
SECRETARY OF THE SENATE
PUBLIC

02 AUG 14 PM 2:58

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

| | | | |
|---|----------------------------------|-------------------|----------------------------------|
| 1. Registrant Name Novartis | | | |
| 2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 701 Pennsylvania Ave. NW Suite 725 City Washington State/Zip (or Country) DC 20004 | | | |
| 3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____ | | | |
| 4. Contact Name James Elkin | Telephone 202-638-7429 | E-mail (optional) | 5. Senate ID # 9204-12 |
| 7. Client Name <input type="checkbox"/> Self Novartis Corporation | | | 6. House ID # 33589000 |

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-Dec 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

| 12. Lobbying Firms | 13. Organizations |
|--|---|
| <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p> | <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$1,720,000.00</u> Expenses (nearest \$)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 603 of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162 of the Internal Revenue Code</p> |

Signature _____

James Elkin

Date _____

8/14/02

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues
**S.754/H.R.1063, Increasing Ability to Enforce Antitrust Laws,
S.812/H.R.1862, Greater Access to Affordable Pharmaceuticals Act,**

17. House(s) of Congress and Federal agencies contacted Check if None
**House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Casserly, Dan | |
| Drake, David | |
| Elkin, James | |
| | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis C too Novartis AG, as its parent, will benefit

Signature  Date 8/14/02

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code FOO (one per page)

- 16. Specific Lobbying issues
 - National Uniformity for Food
 - Genetically Engineered Food Right to Know Act
 - Country of Origin Labeling
 - GMO Labeling

17. House(s) of Congress and Federal agencies contacted Check if None

- Department of Agriculture
- Environmental Protection Agency
- Food & Drug Administration
- House of Representatives
- Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|---------------|---|
| Drake, David | |
| Elkin, James | |
| Haller, Sarah | |
| Rosen, Burt | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
 Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis C too Novartis AG, as its parent, will benefit.

Signature  Date 8/14/02

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

- H.R. 1387, Drug Availability and Health Care Access Improvement Act of 2001,**
- H.R.1530, Prescription Drug Competition Act of 2001,**
- H.R.1624/S.913, Access to Cancer Therapies Act of 2001,**
- S. 1239 , Medicare Rx Drug Discount and Security Act of 2001,**
- S.10 , Medicare Prescription Drug Coverage Act of 2001,**
- S.1135, Medicare Reform Act of 2001,**
- S.1185 , Seniors Prescription Insurance Coverage Equity Act of 2001,**
- S.838 IS, Better Pharmaceuticals for Children Act ,**
- S.880/H.R.1839, Immunosuppressive Drug Coverage Act of 2001,**
- S.982 IS /H.R.2058 IH, Medicare Wellness Act of 2001,**

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|--------------------------|---|
| Bumbaugh, Deborah | |
| Casserly, Dan | |
| Drake, David | |
| Elkin, James | |
| Haller, Sarah | |
| Rosen, Burt | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis C too Novartis AG, as its parent, will benefit.

Signature  Date 8/14/02

Registrant Name: NovartisClient Name: Novartis Corporation

| Item | Description | Data |
|------|-----------------|--|
| 16 | Lobbying Issues | <p> Medicare Prescription Drugs Snowe/Wyden The Senior Prescription Insurance Coverage Equity Act (S.1 Breaux/Thomas Medicare Reform Plan Health Insurance Portability and Accessibility Act FDA Modernization Act Medical Records Privacy - Senators Jeffords, Bennett, Leahy, Kennedy Bill Prospective Payment System Gene Therapy Drug Reimportation Medicare Reform Agriculture Appropriations 2001 - Drug Reimportation Agriculture Appropriation 2001 (FDA funding) Stem Cell Research Pediatric Exclusivity Direct-to-Consumer Advertising PDUFA The Bipartisan Medicare Prescription Drug Act of 2001 (Sen. Kennedy-Dra President Bush's "Helping Hand" proposal </p> |

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues
H.R. 1530, Prescription Drug Competition Act of 2001,
H.R.1387, Drug Availability and Health Care Access Improvement Act of 2001,
HR1624/S913, Access to Cancer Therapies Act,
S. 10, Medicare Prescription Drug Coverage Act of 2001 ,
S.1135, Medicare Reform Act of 2001,
S.1185, Seniors Prescription Insurance Coverage Equity Act of 2001,
S.1239, Medicare Rx Drug Discount & Security Act of 2001,
S.880/H.R.1839, Immunosuppressive Drug Coverage Act of 2001,
S.982 IS/H.R. 2058 IH, Medicare Wellness Act of 2001,

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|--------------------------|---|
| Bumbaugh, Deborah | |
| Cassery, Dan | |
| Drake, David | |
| Elkin, James | |
| Haller, Sarah | |
| Rosen, Burt | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis C too Novartis AG, as its parent, will benefit.

Signature  Date 8/14/02

Registrant Name: NovartisClient Name: Novartis Corporation

| Item | Description | Data |
|------|-----------------|---|
| 16 | Lobbying Issues | Medicare Prescription Drug & Modernization Act The Bipartisan Medicare Prescription Drug Act of 2001 (Sen. Kennedy-Dra President Bush's "Helping Hand" proposal Prospective Payment System Medicare Reform |

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)


16. Specific Lobbying issues
Economic Sanctions
SRM Ban/BSE
China/World Trade Organization
Fast Track Negotiating Authority
Capital Market Sanctions

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Drake, David | |
| Haller, Sarah | |
| Rosen, Burt | |
| | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis C too Novartis AG, as its parent, will benefit.

Signature  Date 8/14/02

